Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)
Closed Posted
- Opportunity number
- PA-25-173
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Categories
-
- Education
- Health
- Eligible applicants
-
- Non-501(c)(3) Nonprofits
- City/Township Governments
- Independent School Districts
- Higher Education Inst. (Private)
- Other
- Public or Indian Housing Auth.
- Special District Governments
- Small Businesses
- For Profit Organizations
- Higher Education Inst. (Public)
- Tribal Organizations (Not Federally Recognized)
- 501(c)(3) Nonprofits
- State Governments
- County Governments
- Tribal Governments (Federally Recognized)
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
This Federal Grant Opportunity, titled "Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)", is seeking to fund preclinical research projects that study how radiopharmaceutical therapy (RPT) agents affect the biology of normal tissue, tumor cells, and the tumor microenvironment. The grant is being offered by the Department of Health and Human Services' National Institutes of Health (NIH). Proposed projects should test hypotheses on how RPT dynamically impacts cancer biology processes, which can inform the development of new RPT-based clinical trials. Eligible applicant types include small businesses, state/local governments, higher education institutions, nonprofits, and other organizations. The application deadline is May 7, 2025.
The STRIPE program provides funding through R21 grants, which have a 2-year duration and do not allow for clinical trials. Recent federal grant awards under the related Cancer Detection and Diagnosis Research (93.394) and Cancer Treatment Research (93.395) programs have ranged from approximately $200,000 to over $1.6 million in total costs. The research is expected to be conducted at the applicant organizations' facilities across the United States.
Synopsis
The STRIPE program seeks to support pre-clinical research projects utilizing state-of-the-art cancer biology methods and model systems that study how radiopharmaceutical therapy (RPT) agents affect the biology of normal tissue, tumor cells and the tumor microenvironment. Ideally, proposed aims will be designed to test hypotheses on how RPT dynamically impacts cancer biology processes, which can serve as the pre-clinical basis for developing new targeting strategies and approaches. Studies supported by this PAR will ultimately inform the rationale and design of new RPT-based clinical trials.
Files
| File | Type | Posted |
|---|---|---|
| PA-25-173-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity